Viriom, member of ChemRar High-Tech Center, presented the results of the clinical studies of a domestic innovation for treatment of patients with HIV infection - Elsulfavirine (VM-1500, Elpivirin), in the Moscow City Hall, where the XIV Moscow Assembly "Health of the Capital" was held from 19 to 20 November.
In 2009 Viriom signed a licensing agreement with the Swiss company "F. Hoffmann - La Roche" and acquired the rights to develop and produce innovative drugs for the treatment of HIV/AIDS in Russia and the CIS. Under the terms of the agreement, Roche provided Viriom with pre-clinical candidates belonging to the new class of non-nucleoside inhibitors of reverse transcriptase (NNRTI). Roche has also agreed to contribute its expertise in the HIV field through scientific coaching and representation on Viriom’s Board of Directors.
Five early clinical studies have been completed to date with results demonstrating the superiority of Elsulfavirine over existing treatments in the same class in terms of efficacy against HIV-1, including mutants, resistant to other NNRTIs. The drug demonstrated a good safety and tolerability profile as well as favorable pharmacokinetic properties in healthy volunteers and in patients with chronic HIV-1 infection. Currently, Elsulfavirine is in Phase III of clinical studies carried out in 18 AIDS Prevention and Control Centres across the Russian Federation.
Viriom expresses extreme gratitude to the leading experts in the field of HIV, who are actively participating in this project.
Special edition of Komsomolskaya Pravda on the results of the Moscow Assembly "Health of the Capital", "Russia's AIDS drugs - a reality of today!» http://www.kp.ru/daily/26462/3332711/
Viriom Ltd. is a member of ChemRar group of companies involved in developing innovative antiviral drugs and combinations, treatment methods, and diagnostics. Viriom conducts scientific research in Russia, tapping into the experience and knowledge of Russian scientists, and abroad within the framework of a broad international partnership. The ChemDiv Research Institute is Viriom's major partner in pre-clinical and clinical research. Clinical studies within Russia are conducted at regional centers and on campus of the Moscow City Center for Preventing and Treating AIDS. Among Viriom’s international partners are Roche, Fox Chase Cancer Center (Philadelphia, PA), The Scripps Research Institute (San Diego, CA), Moscow Physics and Technology Institute, and M.P. Chumakov Institute for Poliomyelitis and Viral Encephalitis (Moscow, Russia). The "Viriom" project was approved by the Presidential Commission on Modernization of the Russian Federation. www.viriom.com